LAG3 and renal cell carcinoma: The DUET-4 trial (NCT03849469) is a phase I trial assessing the safety, pharmacokinetics and anti-tumor activity of the new anti-LAG3 drug XmAb22841, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors, including RCC.